Histologically, we observed that lenvatinib-treated s.c. YUMMER1.7 melanomas also had increased necrosis compared with anti-VEGF, which may be a direct effect of cytotoxicity and/or due to decreased tumor-associated blood vessels. This evidence concerns the gene VEGFA and melanoma.